212 related articles for article (PubMed ID: 20234185)
1. HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.
Nardinocchi L; Puca R; Givol D; D'Orazi G
Cell Cycle; 2010 Apr; 9(7):1270-5. PubMed ID: 20234185
[TBL] [Abstract][Full Text] [Related]
2. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.
Nardinocchi L; Puca R; Sacchi A; Rechavi G; Givol D; D'Orazi G
PLoS One; 2009 Aug; 4(8):e6819. PubMed ID: 19714248
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.
Nardinocchi L; Puca R; Sacchi A; D'Orazi G
Mol Cancer; 2009 Jan; 8():1. PubMed ID: 19128456
[TBL] [Abstract][Full Text] [Related]
4. HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation.
Nardinocchi L; Puca R; D'Orazi G
Aging (Albany NY); 2011 Jan; 3(1):33-43. PubMed ID: 21248371
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycemia triggers HIPK2 protein degradation.
Baldari S; Garufi A; Granato M; Cuomo L; Pistritto G; Cirone M; D'Orazi G
Oncotarget; 2017 Jan; 8(1):1190-1203. PubMed ID: 27901482
[TBL] [Abstract][Full Text] [Related]
6. Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells.
Nardinocchi L; Puca R; Givol D; D'Orazi G
FEBS Lett; 2010 Oct; 584(19):4253-8. PubMed ID: 20849851
[TBL] [Abstract][Full Text] [Related]
7. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
Puca R; Nardinocchi L; Givol D; D'Orazi G
Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
9. HIPK2 modulates p53 activity towards pro-apoptotic transcription.
Puca R; Nardinocchi L; Sacchi A; Rechavi G; Givol D; D'Orazi G
Mol Cancer; 2009 Oct; 8():85. PubMed ID: 19828042
[TBL] [Abstract][Full Text] [Related]
10. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.
Chen P; Duan X; Li X; Li J; Ba Q; Wang H
Oncogene; 2020 Apr; 39(14):2863-2876. PubMed ID: 32034309
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth.
Nardinocchi L; Puca R; Guidolin D; Belloni AS; Bossi G; Michiels C; Sacchi A; Onisto M; D'Orazi G
Biochim Biophys Acta; 2009 Feb; 1793(2):368-77. PubMed ID: 19046997
[TBL] [Abstract][Full Text] [Related]
12. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
Mancini F; Pieroni L; Monteleone V; Lucà R; Fici L; Luca E; Urbani A; Xiong S; Soddu S; Masetti R; Lozano G; Pontecorvi A; Moretti F
Oncogene; 2016 Jan; 35(2):228-40. PubMed ID: 25961923
[TBL] [Abstract][Full Text] [Related]
13. Updates on HIPK2: a resourceful oncosuppressor for clearing cancer.
D'Orazi G; Rinaldo C; Soddu S
J Exp Clin Cancer Res; 2012 Aug; 31(1):63. PubMed ID: 22889244
[TBL] [Abstract][Full Text] [Related]
14. Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation.
Garufi A; Pistritto G; Ceci C; Di Renzo L; Santarelli R; Faggioni A; Cirone M; D'Orazi G
PLoS One; 2012; 7(11):e48342. PubMed ID: 23144866
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
D'Orazi G; Garufi A; Cirone M
IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
[TBL] [Abstract][Full Text] [Related]
16. The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death.
He Y; Roos WP; Wu Q; Hofmann TG; Kaina B
Mol Cancer Res; 2019 May; 17(5):1129-1141. PubMed ID: 30796178
[TBL] [Abstract][Full Text] [Related]
17. Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis.
Cecchinelli B; Lavra L; Rinaldo C; Iacovelli S; Gurtner A; Gasbarri A; Ulivieri A; Del Prete F; Trovato M; Piaggio G; Bartolazzi A; Soddu S; Sciacchitano S
Mol Cell Biol; 2006 Jun; 26(12):4746-57. PubMed ID: 16738336
[TBL] [Abstract][Full Text] [Related]
18. Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization.
Polonio-Vallon T; Kirkpatrick J; Krijgsveld J; Hofmann TG
Cell Cycle; 2014; 13(1):115-25. PubMed ID: 24196445
[TBL] [Abstract][Full Text] [Related]
19. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.
D'Orazi G; Cecchinelli B; Bruno T; Manni I; Higashimoto Y; Saito S; Gostissa M; Coen S; Marchetti A; Del Sal G; Piaggio G; Fanciulli M; Appella E; Soddu S
Nat Cell Biol; 2002 Jan; 4(1):11-9. PubMed ID: 11780126
[TBL] [Abstract][Full Text] [Related]
20. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.
Rinaldo C; Prodosmo A; Mancini F; Iacovelli S; Sacchi A; Moretti F; Soddu S
Mol Cell; 2007 Mar; 25(5):739-50. PubMed ID: 17349959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
